十五五-新征途-2026年医药产业政策展望

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the biomedical industry in China, highlighting its elevation as a new pillar industry in the national development plan, particularly focusing on biomanufacturing, brain-computer interfaces, high-end medical devices, and innovative drug development [1][2]. Core Insights and Arguments - Policy Direction: The top-level design of the biomedical industry policy emphasizes two core directions: "strong innovation" and "benefiting people's livelihood." The industry is recognized for its economic importance and social function, with a focus on improving the healthcare system [2][3]. - Medicare Adjustments: In 2026, the per capita financial subsidy for Medicare is planned to increase by 24 yuan, a slight decrease from the 30 yuan increase in 2025, indicating a continued trend of increasing government subsidies despite a slight adjustment in growth rate [2]. - Support for Innovative Drugs: The 2025 Medicare drug list adjustment reflects strong support for "true innovation," with 40% of the newly added 114 drugs being first-class new drugs, and 50% of these being biological products [5][6]. - Renewal Rules: The renewal rules for drugs in the Medicare directory show a stable support attitude towards high-value mature products, with 92% of drugs renewing without price reductions [6]. - Commercial Insurance Directory: The first commercial insurance directory introduced in 2025 included 19 out of 141 reported drugs, focusing on high-innovation products and offering significant policy benefits [7][8]. - Accelerating Domestic Drug Access: Measures have been taken to accelerate the access of domestic innovative drugs to hospitals, including a requirement for medical institutions to hold drug committee meetings within three months of the Medicare directory release [9]. Additional Important Content - Consolidation in Retail Pharmacy: The retail pharmacy industry is expected to enter a phase of high-quality development and horizontal mergers starting in 2026, with policies encouraging pharmacies to execute equal outpatient insurance treatment as grassroots medical institutions [11]. - IVD Sector Developments: The IVD sector is seeing significant changes, including a focus on reducing the number of chargeable items and ensuring that AI-assisted diagnostics do not incur additional fees [17][18]. - Medical Device Industry Trends: The medical device industry is experiencing a slowdown in bidding procurement growth, with an expansion of centralized procurement covering about 30% of the industry, particularly in county-level medical communities [19][20]. - Medicare Payment Reform: The upcoming DRG/DIP 3.0 version is expected to provide more specific support for innovation, while a nationwide pilot for traditional Chinese medicine payment by disease will also be initiated [20][21]. - Regulatory Changes: New regulatory measures are being implemented to enhance the efficiency of Medicare fund clearing and to apply AI technology in regulatory processes [22]. This summary encapsulates the key points discussed in the conference call, providing insights into the current state and future direction of the biomedical industry in China.